News | Coronavirus (COVID-19) | December 07, 2020

MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program

MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program #COVID19 #coronavirus

Getty Images


December 7, 2020 — An analysis of lung tissues from patients with different types of pulmonary fibrosis - including cases triggered by COVID-19 - has revealed a promising molecular target to ameliorate the chronic and irreversible disease. Experiments in mouse models of lung fibrosis showed that administering blockers of an epigenetic regulator called MBD2 via intratracheal inhalation protected the mice against fibrotic lung injury, highlighting a potential viable therapy. A poor understanding of what causes pulmonary fibrosis has greatly hindered the development of treatments, and to this day, no effective therapy is available other than lung transplantation. To tackle this limitation, Yi Wang and colleagues studied lung samples from patients with pulmonary fibrosis triggered by one of three causes: SARS-CoV-2 infection, systemic sclerosis-associated interstitial lung disease, or an unknown factor. The researchers also studied mouse models of pulmonary fibrosis, which they induced in the animals by administering the compound bleomycin. All cases of pulmonary fibrosis, they found, were characterized by overexpression of MBD2. This activity localized in areas occupied by macrophages - known contributors to the development of pulmonary fibrosis. To investigate this further, the scientists depleted the Mbd2 gene in macrophages of mice, which protected the animals against pulmonary fibrosis, characterized by markedly reduced macrophage accumulation in the lung following administration of bleomycin. As well, direct administration of liposomes - established carriers of inhaled drugs - loaded with Mbd2 silencer RNA into the trachea of mice protected them from lung injuries and fibrosis. Since MBD2 itself does not affect the essential epigenetic process of DNA methylation, inhibiting the molecule could prove to be a safe way to treat pulmonary fibrosis. However, future studies will first need to assess the impact of altered MBD2 expression in other types of cells relevant to pulmonary fibrosis, the authors say.

For more information: www.aaas.org


Related Content

News | Digital Radiography (DR)

November 28, 2023 — Canon Medical Components USA (CMCU) - Digital Radiography (DR), global leaders in advanced flat ...

Time November 28, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

November 28, 2023 — New research being presented this week at the annual meeting of the Radiological Society of North ...

Time November 28, 2023
arrow
News | Computed Tomography (CT)

November 28, 2023 — Smoking marijuana in combination with cigarettes may lead to increased damage of the lung’s air sacs ...

Time November 28, 2023
arrow
News | RSNA

November 27, 2023 — The executive leadership teams from Canon Inc. and Cleveland Clinic gathered early on day two of the ...

Time November 27, 2023
arrow
News | Radiation Dose Management

November 27, 2023 — Qaelum NV, a leading provider of innovative healthcare solutions, and Philips, a global leader in ...

Time November 27, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

November 27, 2023 — Stronger quadriceps muscles, relative to the hamstrings, may lower the risk of total knee ...

Time November 27, 2023
arrow
News | Digital Radiography (DR)

November 26, 2023 — Konica Minolta Healthcare Americas, Inc., announced today several new solutions in digital ...

Time November 26, 2023
arrow
News | RSNA

November 25, 2023 — 4DMedical, a global technology company and producer of advanced lung function imaging software, has ...

Time November 24, 2023
arrow
News | PET-CT

November 22, 2023 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of the Biograph ...

Time November 22, 2023
arrow
News | Computed Tomography (CT)

November 22, 2023 — Lung cancer is one of the world’s silent killers. By the time patients experience symptoms, the ...

Time November 22, 2023
arrow
Subscribe Now